Ordering from outside the Americas?Switch to the EU store
Recovery & RepairTb
TB-500 5mg
vial · 5 mg
◉Lot numberedLot on every label
✓Research use onlyIn vitro only
❄Cold-chain shippingInsulated, tracked

TB-500

In stockThymosin β4 (1-43)

TB-500 is the name used for synthetic thymosin beta 4, a 43-residue peptide that binds G-actin. Researchers study the parent peptide in cell migration, angiogenesis and wound models.

Select format
Select content
Choose quantity · save more
Need solvent? Add extra below
$49.00
$101.00 more for free shipping

In stock

SequenceAc-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGESCAS77591-33-4FormulaC212H350N56O78SAliasesThymosin β4 (1-43), Tβ4, TB 500, Thymosin beta 4FormatvialContent5 mg

Supplied as a single-chamber lyophilized vial with a colour-coded cap (Recovery & Repair).

Questions about TB-500

How much published research is there on TB-500?

The research library's PubMed search for TB-500 returned 1,195 records on 5 October 2026, 138 of them reviews. The library lists 6 studies chosen for what they measured. ClinicalTrials.gov lists 18 registered studies naming TB-500 (checked 5 October 2026).

Is TB-500 an approved medicine?

No medicinal product containing TB-500 is listed in Drugs@FDA (checked 5 October 2026), and the research material we supply is not a medicine. Drugs@FDA lists no application naming thymosin beta 4 or timbetasin or thymosin beta-4 as an active ingredient (checked 5 October 2026). The WADA 2026 list names thymosin beta 4 and its derivatives, with TB-500 as the example. It is supplied for in-vitro laboratory research only, not for human or veterinary use.

Is TB-500 the same as thymosin beta 4?

TB-500 is the name used for synthetic thymosin beta 4, a 43-residue peptide, and the catalog lists the full-length sequence. The primary literature indexes the parent peptide as thymosin beta 4, so the studies cited on this page concern thymosin beta 4.

How does TB-500 differ from BPC-157?

BPC-157 is a 15-residue synthetic peptide described as a partial sequence of a gastric protein. TB-500 is the name used for synthetic thymosin beta 4, a 43-residue actin-binding peptide. They differ in origin, size and literature, and one rat study has compared each with the combination.

How is the identity of TB-500 confirmed on a certificate?

A research-grade certificate of analysis typically reports identity by mass spectrometry and purity by HPLC. The mass result is read against the average molecular weight of 4963.4 Da listed on this page. The research library's guide to reading a certificate explains each field.

What other names is TB-500 published under?

TB-500 is also written Thymosin β4 (1-43), Tβ4, TB 500 and Thymosin beta 4. The catalog lists it under the name TB-500.

Is this product for human use?

No. Peptency products are supplied for in-vitro research only. Not for human or veterinary use, not for diagnosis or therapy.

Where can I find shipping information?

Current shipping rates and delivery information are on the Shipping & payment page, and the rates that apply to your order are shown at checkout.

For research use only. Not for human or veterinary use.

What is TB-500?

TB-500 is the name used for synthetic thymosin beta 4, a 43-residue peptide that binds G-actin. The catalog lists the full-length sequence. The primary literature indexes the parent peptide as thymosin beta 4, so the studies on this page concern thymosin beta 4. We supply TB-500 as a lyophilized vial for in-vitro laboratory research only.

What are the chemical identifiers of TB-500?

TB-500 has the molecular formula C212H350N56O78S, an average molecular weight of 4963.4 Da and CAS number 77591-33-4.

Chemistry checked against PubChem (CID 16132341), 5 October 2026; full chemistry record in the research library.

What does published research on TB-500 cover?

A PubMed search for TB-500 returned 1,195 records on 5 October 2026, 138 of them reviews. Our research library lists 6 of these studies, chosen for what they measured.

  • Thymosin beta 4 is described as the main G-actin sequestering peptide in mammalian tissue and as a mediator of cell migration, proliferation and differentiation. (Philp et al., FASEB J, 2003; PMID 14500546; Goldstein et al., Expert Opin Biol Ther, 2012; PMID 22074294)
  • The actin-binding region of thymosin beta 4 was mapped and tested for angiogenic activity in endothelial-cell and tissue assays. (Philp et al., FASEB J, 2003; PMID 14500546)
  • In a rat full-thickness wound model re-epithelialisation and wound contraction were measured. (Malinda et al., J Invest Dermatol, 1999; PMID 10469335)
  • Reviews describe thymosin beta 4 expression across human organs during development, and its role in kidney glomerular cells. (Faa et al., Cells, 2024; PMID 38994967)

Mechanism, every cited study and the regulator records are on the TB-500 page of the research library. Papers are listed by what they measured, not as evidence of any use.

How is TB-500 supplied and stored?

TB-500 is supplied as a lyophilized (freeze-dried) powder in a sealed vial, for in-vitro laboratory research only. Our stated storage condition for the sealed lyophilized vial is 2 to 8 °C. The label and the lot certificate carry the lot-specific storage condition and expiry date.

What is the regulatory status of TB-500?

Drugs@FDA lists no application naming thymosin beta 4 or timbetasin or thymosin beta-4 as an active ingredient (checked 5 October 2026).

The WADA 2026 Prohibited List names this substance under S2.3. A WADA entry is a sporting rule, not a statement about legality outside sport.

The WADA 2026 list names thymosin beta 4 and its derivatives, with TB-500 as the example.

A regulator record is information about a database entry. It is not advice and not a statement that any use is lawful or unlawful in any country. How regulators approach research peptides.

Which related research pages and compounds are listed?

Related compounds in the catalog: